SUBSCRIBE: Print / Digital / eNewsletter
Drug costs are increasing, but so is patient cost sharing. That’s raising serious problems for some patients. Here are seven of the most out-of-reach drugs due to high costs, according to industry watchers.
The chain’s move is an attempt to increase relationships with traditionally-loyal pharmacy patients.
Managed Healthcare Executive’s Managed Care Pharmacy Survey identifies different ways specialty pharmacy stakeholders believe they can reduce industry costs moving forward.
As CBD, or cannabidiol, surges in popularity, the FDA held its first public hearing on the chemical that claims to help with a variety of ailments including pain and anxiety.
A new survey shows that while many healthcare executives recognize drug diversion as a problem, few admit to it happening in their organization.
New study compares every state using data like opioid prescriptions and overdose rates to determine where drug problems hit hardest.
From drug price concerns to the evolving role of PBMs to the influence of specialty pharmaceuticals, what healthcare executives think about the future of pharmacy.
The vaccines that could make a big impact on healthcare, from radical new flu vaccines to simplified meningococcal vaccine regimens.
How will payers, providers, and patients respond when a $2 million drug drops into the market?
In the first of many similar cases, the trial of Oklahoma versus Johnson & Johnson could frame who is to blame for the opioid epidemic.
With a more than $2 million price tag, how are payers going to deal with the recently approved Zolgensma?
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
